TNF inhibitor
Eric Dein ericdeinmd
10 months 2 weeks ago
Conversation with @RheumKay on his #ACR24 biosimilar talk for @RheumNow
https://t.co/LzAIGIG4wu https://t.co/CqSYLpJYAh
Dr. John Cush RheumNow
10 months 2 weeks ago
JAK-pot! How fast do DMARDs work?
Dr. Mike Putman interviews Dr. Kim Lauper about abstract 0501, How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients… https://t.co/GO9EwyrVpV https://t.co/lELE5SJW5i
Richard Conway RichardPAConway
10 months 2 weeks ago
TNFis preventing cancer compared to placebo, and JAKi being neutral to placebo and maybe preventing haem cancers also. #ACR24 abstract 0989 was certainly provocative. I've shared my thoughts on @RheumNow https://t.co/yQFoUGifEN
Mrinalini Dey DrMiniDey
10 months 2 weeks ago
What is the effect of cs/bDMARDs on weight in #PsA?
⬇️Weight loss seen with:
IL17i
IL23i
csDMARDs
⬆️Weight gain seen with:
TNFi
IL12/23i
Important to consider #comorbidity & #BMI in management decisions in PsA
Ab2639 #ACR24 @RheumNow
Eric Dein ericdeinmd
10 months 2 weeks ago
A#2583
Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring
MOSAIC P4 open label trial
Reduction in inflammation seen in vertebral bodies & posteriolateral, not in facet joints
No changes in SPARCC SIJ, spine - though low baseline SIJ inflammation
@RheumNow #ACR24 https://t.co/3GKEGJbtdc
Antoni Chan MD (Prof) synovialjoints
10 months 2 weeks ago
A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes
Key findings:
- Significant weight loss after starting IL17i, IL23i, and csDMARDs.
- TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn
Caoilfhionn Connolly CaoilfhionnMD
10 months 2 weeks ago
#2286🔬Certolizumab Pegol (CZP) in High RF RA
📊Pooled analysis;N=1180
💥PBO: High RF=more radiographic progression v low RF (Wk24 6.5 v 2.8%,Wk52 17.6 v 10.4%)
💥CZP: min. progression regardless of RF (Wk24 0 v 1.1%;Wk52 5.3 v 3.1%)
#ACR24 @RheumNow https://t.co/koel7SDsUb
Richard Conway RichardPAConway
10 months 2 weeks ago
Tesser et al. Implanted cervical vagus nerve stimulator for b/tsDMARD-IR RA. 242 patients. ACR20 week 12 35% vs 24%. Higher rates of DAS28-CRP LDA/remission. @RheumNow #ACR24 Abstr#L10 https://t.co/OXojHEMkKQ https://t.co/XSt97u7LrR
Eric Dein ericdeinmd
10 months 2 weeks ago
@DianeLacaille Canadian biosimilar exp
Biosimilar transition v originator controls x2 yrs
Weighted model: no decr in ETN biosimilar discontinuation v originator. IFX shows slight decrease - NOT statistical signif
Safety- no difference, slight incr rheum visits
@RheumNow #ACR24 https://t.co/0GMfLAyzOo
Eric Dein ericdeinmd
10 months 2 weeks ago
Biosimilar switching in practice
Hyrich: UK experience
Switching to biosimilar has no immediate benefit to patients but saves NHS money
Allows for gain share that can be re-invested in pt care
Transparency in switching in explaining to pts and offering resource
@RheumNow #ACR24
Eric Dein ericdeinmd
10 months 2 weeks ago
Hyrich:
ETN originator vs biosimilar initiation
- DAS28 - no signif change at B/L, 6mo, 12 mo.
Switch?
Matched pts in ETN switch v cont originator - good b/l control on Rx
-DAS28 maintained w switch
10% did go back to originator, felt less good tho similar DAS
#ACR24 @RheumNow https://t.co/RHRit5CtUu
The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.
Poster Hall